# DBV Technologies S.A.: financial statements, quarterly

DBVT · Nasdaq · CIK 1613780 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/dbvt.md) · [Financials](/companies/dbvt/financials.md) · [Filings](/companies/dbvt/filings.md) · [Insiders](/companies/dbvt/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/dbvt/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [8.9 d](/filings/0001613780-25-000006.md) | [1.4](/filings/0001613780-25-000011.md) | [1.2](/filings/0001613780-25-000016.md) | [1.1](/filings/0001628280-25-046809.md) | [0.5 d](/filings/0001628280-26-021504.md) | [0.8](/filings/0001628280-26-028929.md) | [1.5](/filings/0001628280-26-048453.md) | [2.8](/filings/0001628280-26-067930.md) | [0.6 d](/filings/0001628280-26-021504.md) | [0.9](/filings/0001628280-26-028929.md) | [0.7](/filings/0001628280-26-048453.md) | [1.6](/filings/0001628280-26-067930.md) |
| Research and development | $m | [12.8 d](/filings/0001613780-25-000006.md) | [21.4](/filings/0001613780-25-000011.md) | [25.4](/filings/0001613780-25-000016.md) | [23.7](/filings/0001628280-25-046809.md) | [18.9 d](/filings/0001628280-26-021504.md) | [21.5](/filings/0001628280-26-028929.md) | [33.7](/filings/0001628280-26-048453.md) | [28.6](/filings/0001628280-26-067930.md) | [32.9 d](/filings/0001628280-26-021504.md) | [33.4](/filings/0001628280-26-028929.md) | [31.2](/filings/0001628280-26-048453.md) | [47.0](/filings/0001628280-26-067930.md) |
| Operating income | $m | [(11.9) d](/filings/0001613780-25-000006.md) | [(28.6)](/filings/0001613780-25-000011.md) | [(33.8)](/filings/0001613780-25-000016.md) | [(30.3)](/filings/0001628280-25-046809.md) | [(23.9) d](/filings/0001628280-26-021504.md) | [(26.6)](/filings/0001628280-26-028929.md) | [(41.1)](/filings/0001628280-26-048453.md) | [(34.3)](/filings/0001628280-26-067930.md) | [(45.1) d](/filings/0001628280-26-021504.md) | [(47.9)](/filings/0001628280-26-028929.md) | [(50.6)](/filings/0001628280-26-048453.md) | [(64.8)](/filings/0001628280-26-067930.md) |
| Income tax | $m | [(0.0) d](/filings/0001613780-25-000006.md) | [0.0](/filings/0001613780-25-000011.md) | [0.0](/filings/0001613780-25-000016.md) | [0.0](/filings/0001628280-25-046809.md) | [0.0 d](/filings/0001628280-26-021504.md) | [0.0](/filings/0001628280-26-028929.md) | [0.1](/filings/0001628280-26-048453.md) | [0.0](/filings/0001628280-26-067930.md) | [0.4 d](/filings/0001628280-26-021504.md) | [0.2](/filings/0001628280-26-028929.md) | [0.2](/filings/0001628280-26-048453.md) | [0.3](/filings/0001628280-26-067930.md) |
| Net income | $m | [134 d](/filings/0001193125-25-100826.md) | [(27.3)](/filings/0001628280-25-046809.md) | [(33.1)](/filings/0001628280-25-046809.md) | [(30.4)](/filings/0001628280-25-046809.md) | [(23.0) d](/filings/0001628280-26-021504.md) | [(27.1)](/filings/0001628280-26-067930.md) | [(41.9)](/filings/0001628280-26-067930.md) | [(33.2)](/filings/0001628280-26-067930.md) | [(44.8) d](/filings/0001628280-26-021504.md) | [(47.6)](/filings/0001628280-26-067930.md) | [(50.4)](/filings/0001628280-26-067930.md) | [(64.5)](/filings/0001628280-26-067930.md) |
| Diluted EPS | $ per share | not reported | [(0.28)](/filings/0001613780-25-000011.md) | [(0.34)](/filings/0001613780-25-000016.md) | [(0.32)](/filings/0001628280-25-046809.md) | not reported | [(0.26)](/filings/0001628280-26-028929.md) | [(0.31)](/filings/0001628280-26-048453.md) | [(0.24)](/filings/0001628280-26-067930.md) | not reported | [(0.11)](/filings/0001628280-26-028929.md) | [(0.12)](/filings/0001628280-26-048453.md) | [(0.14)](/filings/0001628280-26-067930.md) |
| Basic EPS | $ per share | not reported | [(0.28)](/filings/0001613780-25-000011.md) | [(0.34)](/filings/0001613780-25-000016.md) | [(0.32)](/filings/0001628280-25-046809.md) | not reported | [(0.26)](/filings/0001628280-26-028929.md) | [(0.31)](/filings/0001628280-26-048453.md) | [(0.24)](/filings/0001628280-26-067930.md) | not reported | [(0.11)](/filings/0001628280-26-028929.md) | [(0.12)](/filings/0001628280-26-048453.md) | [(0.14)](/filings/0001628280-26-067930.md) |

- Revenue: us-gaap:Revenues
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [141](/filings/0001613780-25-000006.md) | [102](/filings/0001193125-24-133228.md) | [66.2](/filings/0001193125-24-188853.md) | [46.4](/filings/0001613780-24-000007.md) | [32.5](/filings/0001628280-26-021504.md) | [13.0](/filings/0001613780-25-000011.md) | [103](/filings/0001613780-25-000016.md) | [69.8](/filings/0001628280-25-046809.md) | [194](/filings/0001628280-26-067930.md) | [229](/filings/0001628280-26-028929.md) | [175](/filings/0001628280-26-048453.md) | [166](/filings/0001628280-26-067930.md) |
| Current assets | $m | [159](/filings/0001613780-25-000006.md) | [120](/filings/0001193125-24-133228.md) | [90.0](/filings/0001193125-24-188853.md) | [68.8](/filings/0001613780-24-000007.md) | [44.4](/filings/0001628280-26-021504.md) | [29.1](/filings/0001613780-25-000011.md) | [121](/filings/0001613780-25-000016.md) | [88.9](/filings/0001628280-25-046809.md) | [213](/filings/0001628280-26-067930.md) | [247](/filings/0001628280-26-028929.md) | [202](/filings/0001628280-26-048453.md) | [190](/filings/0001628280-26-067930.md) |
| Total assets | $m | [183](/filings/0001613780-25-000006.md) | [146](/filings/0001193125-24-133228.md) | [114](/filings/0001193125-24-188853.md) | [93.1](/filings/0001613780-24-000007.md) | [65.7](/filings/0001628280-26-021504.md) | [50.6](/filings/0001613780-25-000011.md) | [143](/filings/0001613780-25-000016.md) | [110](/filings/0001628280-25-046809.md) | [234](/filings/0001628280-26-067930.md) | [266](/filings/0001628280-26-028929.md) | [223](/filings/0001628280-26-048453.md) | [215](/filings/0001628280-26-067930.md) |
| Current liabilities | $m | [37.3](/filings/0001613780-25-000006.md) | [26.5](/filings/0001193125-24-133228.md) | [27.4](/filings/0001193125-24-188853.md) | [30.9](/filings/0001613780-24-000007.md) | [31.1](/filings/0001628280-26-021504.md) | [40.4](/filings/0001613780-25-000011.md) | [49.4](/filings/0001613780-25-000016.md) | [49.5](/filings/0001628280-25-046809.md) | [58.0](/filings/0001628280-26-067930.md) | [51.8](/filings/0001628280-26-028929.md) | [54.3](/filings/0001628280-26-048453.md) | [58.5](/filings/0001628280-26-067930.md) |
| Total liabilities | $m | [42.8](/filings/0001613780-25-000006.md) | [34.2](/filings/0001193125-24-133228.md) | [35.1](/filings/0001193125-24-188853.md) | [39.0](/filings/0001613780-24-000007.md) | [38.3](/filings/0001628280-26-021504.md) | [47.7](/filings/0001613780-25-000011.md) | [57.2](/filings/0001613780-25-000016.md) | [57.6](/filings/0001628280-25-046809.md) | [64.9](/filings/0001628280-26-067930.md) | [58.4](/filings/0001628280-26-028929.md) | [62.8](/filings/0001628280-26-048453.md) | [66.7](/filings/0001628280-26-067930.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001628280-26-067930.md) | not reported | not reported | [0.2](/filings/0001628280-26-067930.md) |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [140](/filings/0001628280-26-021504.md) | [112](/filings/0001628280-25-046809.md) | [79.1](/filings/0001628280-25-046809.md) | [54.0](/filings/0001628280-25-046809.md) | [27.4](/filings/0001628280-26-067930.md) | [2.9](/filings/0001628280-26-067930.md) | [86.2](/filings/0001628280-26-067930.md) | [52.9](/filings/0001628280-26-067930.md) | [169](/filings/0001628280-26-067930.md) | [208](/filings/0001628280-26-067930.md) | [160](/filings/0001628280-26-067930.md) | [149](/filings/0001628280-26-067930.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(13.7) d](/filings/0001613780-25-000006.md) | [(34.7)](/filings/0001613780-25-000011.md) | [(35.1) d](/filings/0001613780-25-000016.md) | [(22.5) d](/filings/0001628280-25-046809.md) | [(12.3) d](/filings/0001628280-26-021504.md) | [(19.7)](/filings/0001628280-26-028929.md) | [(33.9) d](/filings/0001628280-26-048453.md) | [(32.4) d](/filings/0001628280-26-067930.md) | [(35.2) d](/filings/0001628280-26-021504.md) | [(49.1)](/filings/0001628280-26-028929.md) | [(52.6) d](/filings/0001628280-26-048453.md) | [(51.5) d](/filings/0001628280-26-067930.md) |
| Capital expenditure | $m | [0.4 d](/filings/0001613780-25-000006.md) | [1.3](/filings/0001613780-25-000011.md) | [0.7 d](/filings/0001613780-25-000016.md) | [0.4 d](/filings/0001628280-25-046809.md) | [(0.1) d](/filings/0001628280-26-021504.md) | [0.0](/filings/0001628280-26-028929.md) | [0.0 d](/filings/0001628280-26-048453.md) | [0.2 d](/filings/0001628280-26-067930.md) | [0.3 d](/filings/0001628280-26-021504.md) | [0.4](/filings/0001628280-26-028929.md) | [0.4 d](/filings/0001628280-26-048453.md) | [2.2 d](/filings/0001628280-26-067930.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [94.0](/filings/0001193125-24-133228.md) | [94.3](/filings/0001193125-24-188853.md) | [96.1](/filings/0001613780-24-000007.md) | [96.2](/filings/0001613780-25-000011.md) | [96.2](/filings/0001613780-25-000016.md) | [96.2](/filings/0001628280-25-046809.md) | [103](/filings/0001628280-26-028929.md) | [134](/filings/0001628280-26-048453.md) | [137](/filings/0001628280-26-067930.md) | [428](/filings/0001628280-26-028929.md) | [434](/filings/0001628280-26-048453.md) | [451](/filings/0001628280-26-067930.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 314,388,807 at 2026-10-26, from the cover of the [10-Q filed 2026-10-28](/filings/0001628280-26-067930.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 29, 2026, 05:16 ET. No prices; not investment advice.